Adimmune Corp
Adimmune Corp is a biotechnology company focused on the research and development of pharmaceutical products, primarily operating in the healthcare sector.
Business. Adimmune Corp (4142.TW) is a pharmaceutical company engaged in the research and development of immunotherapies. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Pharmaceuticals sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Adimmune Corp (4142.TW) is a pharmaceutical company engaged in the research and development of immunotherapies. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Stock Exchange. As specific operating segment and geographic data are not provided, the company is described at the industry level within the Pharmaceuticals sector.
Adimmune Corp's capital structure shows a debt-to-equity ratio of 0.57, indicating a moderate level of leverage. The company's liquidity position is characterized by a current ratio of 2.12, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents amount to 723,001,000 TWD, which is significantly lower than its long-term debt of 2,830,247,000 TWD, resulting in a negative net cash position.
The company's profitability metrics are concerning, with a return on equity (ROE) of -4.85% and a return on assets (ROA) of -2.93%. These figures indicate that Adimmune Corp is not generating returns that meet the cost of equity or assets, which is below the typical performance of the biotechnology industry.
Adimmune Corp's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but its operations are primarily based in Taiwan. This concentration may expose the company to specific market risks, including regulatory changes and economic downturns in the region.
The company's growth trajectory is mixed. While it reported revenue of 1,401,501,000 TWD, it also experienced a net loss of 239,889,000 TWD. The operating cash flow is negative at -5,446,000 TWD, and the free cash flow is -375,306,000 TWD, indicating that the company is not generating sufficient cash from operations to sustain its activities without external financing.
Risk factors for Adimmune Corp include its negative net cash position and the potential for dilution, although the risk of dilution is currently assessed as low. The company's liquidity risk is moderate, and its credit risk is influenced by its high leverage and negative cash flows. The company has not disclosed any recent significant events in its filings or transcripts that would indicate a change in its strategic direction or financial health.
Recent events and disclosures do not show any significant changes in the company's operations or financial strategy. The company's latest earnings report showed a loss per share of -0.57 TWD, which aligns with the broader trend of financial underperformance.
- Adimmune Corp has a negative return on equity and assets, indicating poor profitability.
- The company's liquidity position is moderate, with a current ratio of 2.12.
- Adimmune Corp's revenue is concentrated in a single business segment, increasing its exposure to market-specific risks.
- The company's growth is constrained by negative operating and free cash flows.
- The risk of dilution is currently low, but the company's financial position may require additional financing in the future.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Adimmune Corp Market data — financials · 2026-05-26
- Adimmune Corp Market data — analyst estimates · 2026-05-26
Ownership & reference
Leadership
- Chi-Shean ChanChairman of the Board, Chief Executive Officer